JEFFERIES ON EMCURE PHARMA ; BUY | TARGET RAISED TO ₹2,500 FROM ₹2,320

• Raises FY27 revenue growth guidance to over 20% from mid-teens earlier. • Targets 100 bps improvement in operating margins. • Amphotericin B expansion across 20 European countries expected to support international growth. • Upcoming Treprostinil launch to drive further growth in international markets. • Domestic business recovery and new product approvals strengthen growth outlook. • Raises FY27–29 EPS estimates by 3–4%.

EMCURE PHARMACEUTICALS L

← Back to feed